| 40.72 0.43 (1.07%) | 12-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 52.55 | 1-year : | 61.39 |
| Resists | First : | 45 | Second : | 52.55 |
| Pivot price | 41.13  |
|||
| Supports | First : | 37.21 | Second : | 32.4 |
| MAs | MA(5) : | 40.41 |
MA(20) : | 39.93 |
| MA(100) : | 28.97 |
MA(250) : | 0 | |
| MACD | MACD : | 1.4  |
Signal : | 1.8 |
| %K %D | K(14,3) : | 55.3 |
D(3) : | 56 |
| RSI | RSI(14): 55.7 |
|||
| 52-week | High : | 45 | Low : | 7.25 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SION ] has closed above bottom band by 45.1%. Bollinger Bands are 3.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 42.07 - 42.27 | 42.27 - 42.48 |
| Low: | 39.44 - 39.65 | 39.65 - 39.86 |
| Close: | 40.38 - 40.72 | 40.72 - 41.05 |
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Fri, 28 Nov 2025
Sionna Therapeutics (SION): Examining Valuation Following Recent Share Price Surge - Sahm
Thu, 27 Nov 2025
Sionna Therapeutics (NASDAQ:SION) Director Sells $71,184.00 in Stock - MarketBeat
Wed, 26 Nov 2025
OrbiMed Advisors sells Sionna Therapeutics (SION) stock worth $4.8m - Investing.com
Wed, 26 Nov 2025
Major Stock Sell-Off by Sionna Therapeutics Directors! - TipRanks
Mon, 24 Nov 2025
Sionna Therapeutics (Nasdaq: SION) to Present at Evercore and Citi Investor Events - Stock Titan
Wed, 19 Nov 2025
Ra Capital sold Sionna Therapeutics (SION) shares worth $5.5m - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 45 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 6.9 (%) |
| Held by Institutions | 93.5 (%) |
| Shares Short | 2,970 (K) |
| Shares Short P.Month | 3,370 (K) |
| EPS | -1.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.5 % |
| Return on Equity (ttm) | -28.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -61 (M) |
| Levered Free Cash Flow | -40 (M) |
| PE Ratio | -22.63 |
| PEG Ratio | 0 |
| Price to Book value | 5.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -29.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|